• ResMed now has the most complete full face mask portfolio, the “right mask for every user”
• 3 out of 4 CPAP users prefer AirFit F30i to other tube-up full face mask
SAN DIEGO-Monday 20 January 2020 [ AETOS Wire ]
(BUSINESS WIRE)
-- ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit F30i, its
first tube-up full face CPAP mask, rounding out the most complete full
face mask portfolio on the market.
Full face
CPAP users can now choose between a tube-up or tube-down connection,
compact under-the-nose or traditional over-the-nose cushion styles, and
even memory foam versus silicone cushion.
AirFit F30i’s
tube-up design makes it easier to sleep in any position. The cushion
rests under the nose to help prevent next-day red marks, soreness, and
irritation on the nasal bridge. Plus, a quick-release elbow allows users
to quickly disconnect and reattach the mask from its tubing at night
without taking the mask off.
Three out of
four CPAP users prefer AirFit F30i to its competitor’s tube-up full face
mask for overall performance in a direct comparison study. Those same
users preferred AirFit F30i’s seal nearly 2 to 1 and comfort nearly 3 to
1. ResMed credits AirFit F30i’s strong favor to years of research and
development into the preferences of patients and HME providers.
“ResMed has
the right mask for every CPAP user,” said Jim Hollingshead, president of
ResMed’s Sleep business. “AirFit F30i provides a reliable seal and a
comfortable under-the-nose fit for active sleepers who need a full face
mask but want the flexibility of a tube-up design. AirFit F30i rounds
out our world-leading portfolio of full face masks designed to meet
patients’ and HME providers’ every need.”
AirFit F30i
also completes ResMed’s “Freedom” category of tube-up masks, offering an
option for every CPAP user. The nasal tube-up AirFit N30i came out in
January 2019 and the nasal pillows tube-up AirFit P30i arrived in April.
AirFit F30i is now available in the United States, Canada, and most of Europe, with other countries to follow.
About ResMed
At ResMed
(NYSE: RMD) (ASX: RMD) we pioneer innovative solutions that treat and
keep people out of the hospital, empowering them to live healthier,
higher-quality lives. Our cloud-connected medical devices transform care
for people with sleep apnea, COPD, and other chronic diseases. Our
comprehensive out-of-hospital software platforms support the
professionals and caregivers who help people stay healthy in the home or
care setting of their choice. By enabling better care, we improve
quality of life, reduce the impact of chronic disease, and lower costs
for consumers and healthcare systems in more than 140 countries. To
learn more, visit ResMed.com and follow @ResMed.
Photos/Multimedia Gallery Available: https://www.businesswire.com/news/home/52160652/enContacts
For media
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
For investors
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
